Hematology-OncologyB-cell lymphomaferroptosis
Breaking Ferroptosis Resistance: PRMT5 Inhibition Emerges as a Game-Changer in B-Cell Lymphoma Therapy
By MedXY|Apr 21, 2026
PRMT5 inhibition sensitizes B-cell lymphomas to ferroptosis by disrupting the PRMT5-ATF5-SLC7A11 axis, offering a novel therapeutic strategy for relapsed or refractory disease.